|
abstracts for 4 of the 11 articles
Early Pathogenesis of Atherosclerosis:
The Childhood Obesity L. Amati, M. Chiloiro, E. Jirillo and V. Covelli
Obesity represents a chronic inflammatory status and adipocytes release either cytokines or an array of adipokines
such as leptin, endowed with immunomodulating and systemic activities. The involvement of cytokines in obesity as well as
of the adipokine leptin is supported by the notion that weight reduction normalizes mediators of inflammation.
In
this framework, we will demonstrate that in obese children, subjected for a period of six months to a hypocaloric diet, reduction
of major biochemical and anthropometric parameters correlates with a normalization of immune status. Infact, absolute numbers
of CD4+ cells and CD4/CD8 ratio increase, while leptin values fluctuate within normal ranges, being this adipokine involved
in the modulation of either innate or adaptive immune responses.
In the discussion, the immune abnormalities detected
in obesity will be pointed out and emphasis will be placed on the increased frequency of infectious episodes occurring in
obese adolescent and adults. Finally, the infectious etiology of obesity will be illustrated in the sense that adipocytes
interacting with infectious agents may cause obesity.
Taken together, the bulk of available data indicate that childhood
obesity should be prevented or reduced to avoid more serious complications in adulthood.
Inflammation of the gums has been known for at least 10 years as statistically relevant to atherosclerosis—jk
Porphyromonas Gingivalis Mediated
Periodontal Disease and Atherosclerosis: Disparate Diseases with Commonalities in Pathogenesis Through TLRs F.C. Gibson
III and C.A. Genco
Toll-like receptors (TLRs) are a group
of pathogen-associated molecular pattern receptors, which play an important role in in-nate immune signaling in response to
microbial infection. It has been demonstrated that TLRs are differentially up regulated in response to microbial infection
and chronic inflammatory diseases such as atherosclerosis. Furthermore hyperlipidemic mice deficient in TLR2, TLR4, and MyD88
signaling exhibit diminished inflammatory responses and decreased atherosclerosis. Accumulating evidence has implicated specific
infectious agents including the periodontal disease pathogen Porphyromonas gingivalis in the progression of atherosclerosis.
Evidence in humans suggesting that periodontal infection predisposes to atherosclerosis is derived from studies demonstrating
that the periodontal pathogen P. gingivalis resides in the wall of atherosclerotic vessels and seroepidemiological
studies demonstrating an association between pathogen-specific IgG antibodies and atherosclerosis. We have established that
the inflammatory signaling pathways that P. gingivalis utilizes is dependent on the cell type and this specificity
clearly influences innate immune signaling in the context of local and distant chronic inflammation induced by this pathogen.
We have demonstrated that P. gingivalis requires TLR2 to induce oral in-flammatory bone lose in mice. Furthermore, we have demonstrated that P. gingivalis infection accelerates atherosclerosis in hyperlipidemic
mice with an associated increase in expression of TLR2 and TLR4 in atherosclerotic lesions. Our recent work with P.
gingivalis has demonstrated the effectiveness of specific intervention strategies (immunization) in the prevention of
pathogen-accelerated atherosclerosis. Improved understanding of the mechanisms driving infection, and chronic inflammation
during atherosclerosis may ultimately provide new targets for therapy.
Leptin and Adipocytokines: Bridging
the Gap Between Immunity and Atherosclerosis G. Matarese, C. Mantzoros and A. La Cava
The role of the adipose tissue in immunity has recently emerged, and there is now ample evidence
that this role is elucidated by a number of cytokine-like hormones produced by adipocytes – called adipokines. The most
relevant adipokines are leptin, adiponectin and visfatin, and all have marked effects on metabolic and immune function. The discovery of adipokines has led to the development of a novel concept that the pathogenesis of atherosclerosis
can be associated with low-degree inflammation associated with slow (auto)immune attack of the endothelial wall of arteries.
This model considers therefore adipokines as the bridge between atherosclerosis, inflammation and immunity. We review here
the most recent advances on adipokine research, with a particular emphasis on the model that considers atherosclerotic lesions
as effects of the (auto)immune-mediated damage of the endothelium that is sustained by low-degree chronic inflammation typical
of obesity and metabolic syndrome.
Advanced Glycation: A Novel Outlook
on Atherosclerosis C.L. Price and S.C. Knight
Atherosclerosis
is a major global cause of morbidity and mortality, and diabetes patients are at increased risk of coronary heart disease
development. Advanced glycation of proteins occurs in the body due to raised concentrations of reducing
sugars and reactive oxygen species, and is a causal factor behind complications of diabetes. Glycated proteins, through alteration
of protein structure and function, and from ligation with their receptors, lead to widespread vascular damage. The
α-oxoaldehyde, methylglyoxal (MG) is the most reactive glycation precursor, and is increased in the blood of diabetes
patients. There is debate about the triggering events leading to atherosclerosis, but the inflammatory
action of glycated proteins, including those with MG adducts, through their receptor, RAGE, is a major candidate for initiating
plaque formation. In addition glycation may cause cross-links on proteins of the extracellular matrix, stiffening arteries
and ‘trapping’ other macromolecules. MG is also likely to form adducts on many other proteins, enzymes, lipids,
DNA or RNA, changing their structure, and may disrupt enzyme activity, hormone regulation and immune function. In the latter
context, MG disrupts function of the potent antigen presenting cells, dendritic cells. This effect may be a double edged sword:
Poor control of infections may contribute to persistent inflammation, whilst inhibition of immune activation by dendritic
cells may inhibit plaque progression. This review aims to present these ideas as a novel slant on the role of the glycation
process in atherosclerosis.
Immune-Mediated Mechanisms in Atherosclerosis:
Prevention and Treatment of Clinical Manifestations J.J. Goronzy, C.M. Weyand and A. Niessner
Accumulation of inflammatory cells identifies atherosclerotic
plaque at risk for rupture. Typically, activated immune cells oc-cupy the rupture-prone areas of the atherosclerotic lesion.
These cells are an appealing therapeutic target for novel strategies of plaque stabilization. Biologic consequences of plaque
inflammation ultimately depend not only on the cellular players populating the lesion but also on triggers of immune activation
originating from within the plaque or arriving from the circulation, and immune effector mechanisms that mediate cellular
damage and plaque destabilization. Recent studies have provided insights into particular immune mechanisms in the atherosclerotic
plaque that contribute to plaque vulnerability. This knowledge provides the basis for potential immunomodulatory therapies
in cardiovascular disease. These therapeutic approaches can be classified as (1) immunomodulatory effects of existing therapies,
(2) therapies targeting inflammatory triggers, and (3) agents inhibiting specific immune mechanisms.
Those who have a financial interest in the outcome manipulate the results, Major study finds that all 37 journal articles positive effects over stated; the average was 32%. Statins cause erectile
dysfunction, cognitive imparement, and cancer.
Lipitor (2011) lifetime sales $131
billion, tops all drugs. Plavix at
$60 billion is second.
STATINS CANCER Link
52% short term
LA Times, Health section, July 21, 2008 -- excerpts
Vytorin, the
combination drug (simvastatin (better known by its commercial name Zocor) and ezetimibe--known as Zetia) prescribed to lower
cholesterol, sustained another blow today, when the author of a major clinical trial announced that the medication had failed
to drive down hospitalization and death due to heart failure in patients with narrowing of the aortic valve. In the process,
researchers in Norway detected a significant blip in cancers in the 1,800 subjects they followed
Today's findings
suggested something more ominous: the incidence of cancer -- and of dying of cancer -- was significantly higher in the patients
taking Vytorin. Altogether, 67 patients on placebo developed cancer during the trial.
Among subjects on Vytorin, 102 developed cancers of various kinds.* This
is the second adverse press—the first being in March 08, when the ENHANCE trial found that Vytorin fared no better than
a placebo at reducing plaque buildup on the walls of patients' arteries.* *
Comments
by jk
Simvastatin (Zocor) is off patent. Thus in a scramble for profits a combination drug (on patent) was introduced. Direct to consumer market cost $155 in 07—mainly TV ads.
*
The pressing issue is that since the development of Statins, the very
first animal studies in the 60s it has been known that Statins increase the incidents of cancer. However, nearly all studies done thereafter have not included cancer.
*
Several studies have failed to find a reduction in the build of plaque, even thought the statins including Zocor, reduce
LDL and cholesterol. Few studies include the
principle reason for taking a statin, namely a reduction in the death rate. Claims
for such reduction probably entail a failure to control the contravening variable, aspirin usage. Given a pile of evidence, including the very mechanism of plaque formation, which involves inflammation
process, I must conclude that the use of statins is highly suspect. Given the
harm done including cognitive impairment, weakness, and cancer, if my skepticism is born out, the harm done by statins as
a course of treatment will far surpass that of VIOXX which killed over 200,000 people world wide by accelerating atherosclerosis.
EXTENDED RELEASE NIACIN IS A SAFER, AND A MORE EFFECTIVE WAY TO LOWER
MI RISK!
|